Skip to main content
. Author manuscript; available in PMC: 2018 May 2.
Published in final edited form as: J Subst Abuse Treat. 2016 Dec 30;74:71–79. doi: 10.1016/j.jsat.2016.12.009

Table 1.

Baseline characteristics of study participants.

Education (control) (n = 83)
No. (%)
MI-Only (n = 77) MI + HealthCall (n = 80) Full sample (N = 240) p-value
Female 14 (16.87) 10 (12.99) 15 (18.75) 39 (16.25) 0.61
Ethnicity 0.64
 African American 48 (57.83) 39 (50.65) 45 (56.25) 132 (55.00) b
 Hispanic 17 (20.48) 23 (29.87) 22 (27.50) 62 (25.83) b
 Other 18 (21.69) 15 (19.48) 13 (16.25) 46 (19.17) b
Spanish-speaking 1 (1.20) 0 (0.00) 3 (3.75) 4 (1.67) 0.17
High school education 62 (74.70) 49 (63.64) 54 (67.50) 165 (68.75) 0.31
Married/stable relationship 9 (10.84) 6 (7.79) 11 (13.75) 26 (10.83) 0.49
Employed 10 (12.20) 12 (15.58) 12 (15.00) 34 (14.23) 0.81
Current DSM-IV drug dependencea 14 (17.07) 12 (15.58) 13 (16.25) 39 (16.32) 0.97
Primary drug type 0.95
 Crack 42 (50.60) 38 (49.35) 39 (48.75) 119 (49.58) b
 Cocaine 14 (16.87) 18 (23.38) 18 (22.50) 50 (20.83) b
 Meth 18 (21.69) 15 (19.48) 15 (18.75) 48 (20.00) b
 Heroin 9 (10.84) 6 (7.79) 8 (10.00) 23 (9.58) b
Mean (SD)
Age, years 46.72 (10.32) 47.38 (8.31) 45.53 (9.23) 46.54 (9.34) 0.46
Years since HIV diagnosisc 14.96 (8.15) 15.58 (6.88) 15.75 (8.85) 15.42 (7.99) 0.81
Number of days used (NumDU)d 8.18 (6.46) 9.29 (7.21) 8.54 (6.86) 8.65 (6.83) 0.58
Amount $ spent (QuantU)e 16.12 (23.53) 15.02 (17.61) 16.15 (16.52) 15.78 (19.47) 0.92

MI = motivational interviewing; SD = standard deviation.

a

DSM-IV drug dependence on participant’s primary drug during the 30 days prior to baseline.

b

P-values not given for pair-wise contrasts between each ethnic group or each primary drug type because these-variables were tested as three- and four-level variables, respectively.

c

Mean years since HIV diagnosis computed among HIV+ participants (n = 234); six participants were provided HIV prevention services.

d

During 30 days prior to baseline.

e

Average dollar amount per day used over 30 days prior to baseline.